S.Korea's Celltrion gets FDA OK to make Bristol-Myers' Orencia
Dec 18 (Reuters) - South Korean biotech firm Celltrion Inc said it received approval from U.S. health regulators to serve as a contract manufacturer to make Bristol-Myers Squibb Co's (BMY.N: Quotazione) rheumatoid arthritis drug Orencia.
The supplemental biological licence application was submitted by Bristol-Myers to meet expected long-term demand for the drug, Celltrion said in a statement. (Reporting by Nachiket Kelkar in Bangalore; Editing by Pratish Narayanan)
© Thomson Reuters 2017 Tutti i diritti assegna a Reuters.